PRESS RELEASE published on 07/15/2024 at 09:30, 2 years 4 months ago Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca Andera Partners' portfolio company Amolyt Pharma has been acquired by AstraZeneca for $1.05 billion, enhancing AstraZeneca's Rare Disease late-stage pipeline and bone metabolism franchise Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Andera Partners
BRIEF published on 07/09/2024 at 08:15, 2 years 4 months ago Andera Partners codirige la série A de 63 millions d'euros pour la biotechnologie SciRhom Produits Biopharmaceutiques Maladies Auto-immunes Financement De Série A Partenaires Andera SciRhom
BRIEF published on 07/09/2024 at 08:15, 2 years 4 months ago Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom Series A Financing Biopharmaceuticals Andera Partners Autoimmune Disorders SciRhom
PRESS RELEASE published on 07/09/2024 at 08:10, 2 years 4 months ago Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom to advance novel iRhom2 antibody therapy towards clinical proof-of-concept Andera Partners SciRhom Autoimmune Biotech Series A Round IRhom2 Antibody
BRIEF published on 03/14/2024 at 11:15, 2 years 8 months ago Tubulis, la société de portefeuille d'Andera Partners, obtient un financement de série B2 de 128 millions d'euros Essais Cliniques Tubulis Partenaires Andera Financement De Série B2 Développement ADC
BRIEF published on 03/14/2024 at 11:15, 2 years 8 months ago Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing Clinical Trials Andera Partners Tubulis Series B2 Financing ADC Development
PRESS RELEASE published on 03/14/2024 at 11:10, 2 years 8 months ago Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 financing to accelerate ADC pipeline development Andera Partners Tubulis €128 Million Series B2 ADC Pipeline Biotech Financing
BRIEF published on 03/14/2024 at 09:05, 2 years 8 months ago AstraZeneca acquiert Amolyt Pharma pour un montant pouvant atteindre 1,05 milliard de dollars Acquisition Biopharmaceutique AstraZeneca Amolyt Pharma Maladies Rares
BRIEF published on 03/14/2024 at 09:05, 2 years 8 months ago AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 03/14/2024 at 09:00, 2 years 8 months ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
Published on 11/18/2026 at 23:30, 11 minutes ago Jericho Energy Ventures Provides Update on Oil and Gas Joint Venture Credit Facility
Published on 11/18/2026 at 21:15, 2 hours 26 minutes ago Sparta Capital Ltd. Announces Resumption of Trading
Published on 11/18/2026 at 15:30, 8 hours 11 minutes ago Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
Published on 11/18/2026 at 14:30, 9 hours 11 minutes ago Boron One Announces Non-Binding Heads of Agreement with Multinational Manufacturing Company
Published on 11/18/2026 at 19:30, 4 hours 10 minutes ago LLCP Completes Investment in Empower Technical Services in Partnership with Management
Published on 11/18/2026 at 18:33, 5 hours 7 minutes ago EQS-Adhoc: Medios AG: Medios AG adopts public share buyback program
Published on 11/18/2026 at 18:05, 5 hours 35 minutes ago ALLWYN UNCOVERS 'FEELINGS DEFICIT' AND JOINS FORCES WITH MARIO LOPEZ TO HELP PEOPLE EXPERIENCE MORE FEELINGS THROUGH PLAY
Published on 11/18/2026 at 17:52, 5 hours 48 minutes ago Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 11/18/2026 at 19:14, 4 hours 26 minutes ago Aéroports de Paris S.A - Favourable binding opinion of the French ART
Published on 11/18/2026 at 19:14, 4 hours 26 minutes ago Aéroports de Paris S.A - Avis conforme favorable de l'ART